Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
Inv. presentation
|
|
Outlook Therapeutics, Inc. (ONS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/28/2020 |
8-K
| Asset disposition|
Docs:
|
"Stock Purchase Agreement, by and between the Company and Syntone Ventures LLC",
"Outlook Therapeutics Announces $16.0 Million Private Placement to Advance the Development of ONS-5010 / LYTENAVA™ · Strategic investment at a premium enhances Company’ s ongoing development activities of ONS-5010 / LYTENAVA™ , an investigational ophthalmic formulation of bevacizumab to treat wet AMD, toward FDA approval · Syntone and Outlook to form joint venture to develop and commercialize ONS-5010 / LYTENAVA™ in greater China MONMOUTH JUNCTION, N.J., May 26, 2020 — Outlook Therapeutics, Inc. , a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced it has entered into a Stock Purchase Agreement with Syntone ..." |
|
| 12/18/2018 |
8-K
| Asset disposition, Quarterly results |
| 09/11/2017 |
8-K
| Quarterly results |
|
|